Clinical Trial Update: Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of relacorilant with nab-paclitaxel in recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer has completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Relacorilant (relacorilant)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-04-30